
Reset all filters
01 3Pfizer Canada Inc.
02 1Pfizer Canada ULC
Reset all filters
01 22091663
02 22362481
Reset all filters
01 4Anidulafungin
Reset all filters
01 4Powder for Solution
Reset all filters
01 22013-03-15
02 22020-03-02
Patent Expiration Date : 2013-03-15
Date Granted : 2007-10-30
Brand Name : ERAXIS
Patent Number : 2091663
Filing Date : 1993-03-15
Strength per Unit : 100mg/vial
Dosage Form : Powder for Solution
Human Or VET : Human
Route of Administration : Intravenous
Patent Expiration Date : 2013-03-15
Date Granted : 2007-10-30
Patent Expiration Date : 2020-03-02
Date Granted : 2008-11-04
Brand Name : ERAXIS
Patent Number : 2362481
Filing Date : 2000-03-02
Strength per Unit : 100mg/vial
Dosage Form : Powder for Solution
Human Or VET : Human
Route of Administration : Intravenous
Patent Expiration Date : 2020-03-02
Date Granted : 2008-11-04
Patent Expiration Date : 2013-03-15
Date Granted : 2007-10-30
Brand Name : ERAXIS
Patent Number : 2091663
Filing Date : 1993-03-15
Strength per Unit : 100 mg / Vial
Dosage Form : Powder for Solution
Human Or VET : Human
Route of Administration : Intravenous
Patent Expiration Date : 2013-03-15
Date Granted : 2007-10-30
Patent Expiration Date : 2020-03-02
Date Granted : 2008-11-04
Brand Name : ERAXIS
Patent Number : 2362481
Filing Date : 2000-03-02
Strength per Unit : 100 mg / Vial
Dosage Form : Powder for Solution
Human Or VET : Human
Route of Administration : Intravenous
Patent Expiration Date : 2020-03-02
Date Granted : 2008-11-04